NCI Closes Iressa Trial For NSCLC When Data Indicate No Survival Benefit
U.S., Canada Begin ExCel Trial To Evaluate Aromasin For Breast Cancer Prevention
Avastin Improves PFS In Advanced Breast Cancer
Preoperative Drug Combo Benefits HER-2 Breast Cancer
Combination Radiation/Vaccine May Benefit Some Patients
“Inoperable” Prostate Cancer May Be Operable, Curable
Benefit Seen In Novel Drug That Treats Gleevec Resistance
NCI’s Rosenberg Confirms 2002 Immunotherapy Results
NCI-Approved Clinical Trials
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
